KRAS and cancer: For our preclinical model, we used NCI-H358 (H358) (p53 null, KRAS mutant, STK11 wild-type), a lung adenocarcinoma cell line consisting of 5–18% of aldehyde dehydrogenase positive (ALDH+) cells, a frequently used biomarker for CSCs in cancer cell lines.